Source: JAMA
Area: News
According to research published in JAMA, use of oral fluoroquinolones may increase the risk of developing a retinal detachment; the absolute risk increase (if any) however appears to be small.
The authors note that fluoroquinolones have been linked to several forms of ocular toxicity. Cases reported in the literature include macular detachment with flumequine and retinal detachment with ciprofloxacin. It is thought that breakdown of collagen, possibly secondary to fluoroquinolones therapy, may promote the development of vitreous detachment, leading to an increased risk of retinal detachment.
They therefore sought to examine the association between oral fluoroquinolone use and the risk of retinal detachment, using a pharmacoepidemiological nested case-control study. The study cohort (n=989,591) comprised all patients in British Columbia who had visited an ophthalmologist between 2000 and 2007 (data taken from the British Columbia Linked ...
Daily Archives: 2012/04/04
Stem Cells in Ophthalmology Update 19: ACT Adds Bascom Palmer as Another Clinical Site for Dry AMD Trials
In an announcement today, Advanced Cell Technology said that Bascom Palmer Eye Institute had received IRB approval to become the third U.S. clinical site for testing ACT’s human embryonic stem cell-derived retinal pigment epithelial cells in the treatment of dry age-related macular degeneration. Bascom Palmer, one of the country’s premier eye institutes, joins UCLA’s Jules Stein Eye Institute and the Wills Eye Institute as the third U.S. site participating in the clinical trials.
The Bascom Palmer trial will be led by acclaimed retinal specialist Dr. Philip Rosenfeld, the father of the use of Avastin in the treatment of the wet (Read more...)
Taking a Break
Most of the kids are on Spring Break. Amy and I took a few days off and are not making lots of plans, but, instead, are taking day trips if we can. The two college kids had their respective breaks 2 -3 weeks ago and each have come and gone back to school. With so [...]
Risk Of Serious Eye Disease May Increase With Osteoporosis Drugs
Drugs that are commonly used to prevent osteoporosis may increase the risk of serious inflammatory eye disease in first-time users, found an article in CMAJ (Canadian Medical Association Journal)...
Stress-induced tolerance can prevent glaucoma
Working in mice, scientists at Washington University School of Medicine in St. Louis have devised a treatment that prevents the optic nerve injury that occurs in glaucoma, a neurodegenerative disease that is a leading cause of blindness.
Former ARVO executive director dies
Former Association for Research in Vision and Ophthalmology (ARVO) Executive Director Joanne G. Angle
died March 8. She was 70 and had cancer.
Systemic, localized treatment both effective for uveitis
Both systemic and localized treatment for vision-threatening uveitis are effective in improving visual
acuity and controlling uveitis and macular edema, according to results from the Multicenter Uveitis Steroid
Treatment (MUST) trial as presented by Jennifer E. Thorne, MD, PhD, here at the 24th annual Current Concepts in
Ophthalmology meeting.
Investigational DME agent nears phase II trial
iCo Therapeutics and JDRF, formerly the Juvenile Diabetes Research Foundation, have joined forces in a
phase II clinical trial to investigate the investigational drug iCo-007 as a treatment for diabetic macular edema
(DME).
Oral bisphosphonates linked to ocular side effects
NEW YORK (Reuters Health) - A Canadian study confirms an increased risk of uveitis and scleritis in
first-time users of oral bisphosphonates.
Look deep into women’s eyes in April
Prevent Blindness America (PBA) has designated April as Women's Eye Health and Safety
Month.
Athletes focus of Sports Eye Safety Month
During Sports Eye Safety Month in April, the American Academy of Ophthalmology, through its EyeSmart
program, is reminding athletes to wear appropriate, sport-specific protective eyewear, properly fitted by an
eye-care professional, to prevent a sports-related eye injury.
Optos ships next-generation imaging devices
Medical retinal imaging company Optos plc has delivered its first next-generation ultra-widefield
retinal imaging devices (Daytona) to customers. The new devices have been scaled to accommodate smaller office
spaces while providing high-resolution imaging and adding new autofluorescence capabilities.
May 1 deadline for glaucoma prize
May 1 is the nomination deadline for the New York Academy of Medicine (NYAM) Lewis Rudin Glaucoma
Prize.
Sightpath Medical launches new Web site
Sightpath Medical has launched a new Web site, www.SightpathMedical.com, designed to help ophthalmic
professionals learn about the company's services and locate resources.
Subscribe
